JP2021512071A5 - - Google Patents

Info

Publication number
JP2021512071A5
JP2021512071A5 JP2020540721A JP2020540721A JP2021512071A5 JP 2021512071 A5 JP2021512071 A5 JP 2021512071A5 JP 2020540721 A JP2020540721 A JP 2020540721A JP 2020540721 A JP2020540721 A JP 2020540721A JP 2021512071 A5 JP2021512071 A5 JP 2021512071A5
Authority
JP
Japan
Prior art keywords
nanobodies
composition
epitopes
ecm
pathological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020540721A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512071A (ja
JP7644441B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/015290 external-priority patent/WO2019148037A1/en
Publication of JP2021512071A publication Critical patent/JP2021512071A/ja
Publication of JP2021512071A5 publication Critical patent/JP2021512071A5/ja
Priority to JP2024115829A priority Critical patent/JP2025003912A/ja
Application granted granted Critical
Publication of JP7644441B2 publication Critical patent/JP7644441B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020540721A 2018-01-25 2019-01-25 疾患におけるecmのナノボディに基づく画像化および標的化ならびに開発 Active JP7644441B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024115829A JP2025003912A (ja) 2018-01-25 2024-07-19 疾患におけるecmのナノボディに基づく画像化および標的化ならびに開発

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862621811P 2018-01-25 2018-01-25
US62/621,811 2018-01-25
PCT/US2019/015290 WO2019148037A1 (en) 2018-01-25 2019-01-25 Nanobody based imaging and targeting of ecm in disease and development

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024115829A Division JP2025003912A (ja) 2018-01-25 2024-07-19 疾患におけるecmのナノボディに基づく画像化および標的化ならびに開発

Publications (3)

Publication Number Publication Date
JP2021512071A JP2021512071A (ja) 2021-05-13
JP2021512071A5 true JP2021512071A5 (cg-RX-API-DMAC7.html) 2022-02-02
JP7644441B2 JP7644441B2 (ja) 2025-03-12

Family

ID=67299765

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020540721A Active JP7644441B2 (ja) 2018-01-25 2019-01-25 疾患におけるecmのナノボディに基づく画像化および標的化ならびに開発
JP2024115829A Pending JP2025003912A (ja) 2018-01-25 2024-07-19 疾患におけるecmのナノボディに基づく画像化および標的化ならびに開発

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024115829A Pending JP2025003912A (ja) 2018-01-25 2024-07-19 疾患におけるecmのナノボディに基づく画像化および標的化ならびに開発

Country Status (5)

Country Link
US (3) US11597769B2 (cg-RX-API-DMAC7.html)
EP (1) EP3743443A4 (cg-RX-API-DMAC7.html)
JP (2) JP7644441B2 (cg-RX-API-DMAC7.html)
CN (1) CN112218890A (cg-RX-API-DMAC7.html)
WO (1) WO2019148037A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112218890A (zh) 2018-01-25 2021-01-12 麻省理工学院 在疾病和发展中基于纳米抗体的ecm成像和靶向
EP4047016A1 (en) 2021-02-19 2022-08-24 Université de Strasbourg Anti-tenascin-c (tnc) single-domain antibodies (nanobodies) and use thereof
CN113151177B (zh) * 2021-05-21 2023-11-03 四川大学华西医院 乳腺或乳腺癌组织脱细胞基质及其制备方法和用途
US20240238451A1 (en) * 2021-05-28 2024-07-18 Albert Einstein College Of Medicine Single-domain antigen-dependent antibody-like fusion proteins
WO2023179370A1 (en) * 2022-03-21 2023-09-28 The Hong Kong Polytechnic University Peptidic bispecific antibody, methods for preparation and uses thereof
CN117624360A (zh) * 2022-08-26 2024-03-01 南京融捷康生物科技有限公司 一种抗trem2的单域抗体及其用途
AU2023387779A1 (en) * 2022-12-30 2024-08-22 Remegen Co., Ltd. Bispecific antibody and application thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025175132A1 (en) * 2024-02-15 2025-08-21 Board Of Regents, The University Of Texas System Methods for selecting triple-negative breast cancer patients for targeted therapy using tumor-specific total mrna expression

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076456A2 (en) * 1999-06-14 2000-12-21 The General Hospital Corporation Modulators of fibrosis
US9320792B2 (en) * 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
AU2009245724A1 (en) * 2008-05-09 2009-11-12 Ablynx N.V. Amino acid sequences directed against integrins and uses thereof
ES2769574T3 (es) * 2013-03-15 2020-06-26 Michael C Milone Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
EP3455245A2 (en) * 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutic targeting of non-cellular structures
WO2018014039A1 (en) * 2016-07-15 2018-01-18 Poseida Therapeutics, Inc. Chimeric antigen receptors (cars) specific for muc1 and methods for their use
CN112218890A (zh) 2018-01-25 2021-01-12 麻省理工学院 在疾病和发展中基于纳米抗体的ecm成像和靶向

Similar Documents

Publication Publication Date Title
JP2025511899A5 (cg-RX-API-DMAC7.html)
JP2022538215A5 (cg-RX-API-DMAC7.html)
JP2023116721A5 (cg-RX-API-DMAC7.html)
JP2025160243A5 (cg-RX-API-DMAC7.html)
JP2023166402A5 (cg-RX-API-DMAC7.html)
JP2021028398A5 (cg-RX-API-DMAC7.html)
JP2022541332A5 (cg-RX-API-DMAC7.html)
JP2020010717A5 (cg-RX-API-DMAC7.html)
JP2022116141A5 (cg-RX-API-DMAC7.html)
JP2011506530A5 (cg-RX-API-DMAC7.html)
JP2012509886A5 (cg-RX-API-DMAC7.html)
JP2023514727A5 (cg-RX-API-DMAC7.html)
JP2023100857A5 (cg-RX-API-DMAC7.html)
DK2215119T3 (da) Monoklonale antistoffer der binder til HGM-CSF og medicinske sammensætninger omfattende de samme.
JPWO2022202973A5 (cg-RX-API-DMAC7.html)
JP2008515616A5 (cg-RX-API-DMAC7.html)
JP2012524702A5 (cg-RX-API-DMAC7.html)
JP2023041070A5 (cg-RX-API-DMAC7.html)
JP2023512729A5 (cg-RX-API-DMAC7.html)
JP2012515773A5 (cg-RX-API-DMAC7.html)
JP2020504434A5 (cg-RX-API-DMAC7.html)
JP2023156274A5 (cg-RX-API-DMAC7.html)
JP2023093656A5 (cg-RX-API-DMAC7.html)
JP2023085264A5 (cg-RX-API-DMAC7.html)
JP2022507958A5 (cg-RX-API-DMAC7.html)